Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Francini, Filippo, Pascucci, Alessandra, Francini, Edoardo, Bargagli, Gianluca, Conca, Raffaele, Licchetta, Antonella, Roviello, Giandomenico, Martellucci, Ignazio, Chiriacò, Giorgio, Miano, Salvatora Tindara, Marzocca, Giuseppe, Manganelli, Antonio, Ponchietti, Roberto, Savelli, Vinno, Petrioli, Roberto
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hindawi Publishing Corporation 2011
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3200276/
https://ncbi.nlm.nih.gov/pubmed/22096653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/258689
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge